ABVC BioPharma Unveils Commercial Strategy with BioKey Cayman Subsidiary

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in botanical-derived therapeutics, has announced significant updates regarding its corporate structure and commercialization strategy. The company, which maintains a pipeline of six drugs and one medical device (ABV-1701/Vitargus®) developed through partnerships with prestigious institutions like Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center, is strategically transitioning mature intellectual property assets toward structured commercial pathways. This initiative is being led by Dr. Uttam Patil, ABVC's Chief Executive Officer, who emphasizes that the framework supports ongoing partnership discussions, potential manufacturing collaborations, and formulation-based licensing initiatives to enhance operational transparency and governance alignment across the ABVC group.

Central to this strategy is the establishment of BioKey (Cayman), Inc., a subsidiary designed as a commercial and structural platform to facilitate global manufacturing alignment and regional market entry for ABVC's functional ingredient and nutraceutical portfolio. BioKey Cayman is structured to drive formulation-based licensing initiatives, contract manufacturing collaborations, and co-branding and distribution partnerships, positioning itself to operate as an independent public entity in the future. The company is making progress toward this goal, with plans to provide updates when permissible, aiming to create long-term value in the global nutraceutical and functional health sectors through scalable product development and quality-driven manufacturing.

This corporate update underscores ABVC's commitment to advancing its botanical-based innovations from clinical development to commercialization, leveraging its network of research institutions and subsidiary ecosystem. The news release, available on www.newmediawire.com, highlights the company's forward-looking approach, though it includes cautionary statements about risks such as manufacturing challenges, financing difficulties, and regulatory hurdles. For more details, investors can refer to the SEC's website at http://www.sec.gov, while contact information for Dr. Uttam Patil is provided via email at uttam@ambrivis.com, reinforcing the transparency and strategic focus of ABVC's evolving business model.